SPARC was overexpressed in highly metastatic tumors such as melanoma, breast cancer, and prostate cancer and acted as an anti-tumor factor in anti-angiogenesis, pro-apoptosis, cell proliferation inhibition, and cell cycle arrest in less metastatic tumors such as ovarian cancer, pancreatic cancer, colorectal cancer, and gastric cancer [41]. Here, SPARC is linked to metastatic neoplasm.